Have you seen gene editing and sequencing stocks recently? Source: Connect world / Shutterstock.com Illumina (NASDAQ:ILMN) is up 20% over the past three months. Beam Therapeutics (NASDAQ:BEAM) is up 45%. Editas Medicine (NASDAQ:EDIT) is up 90%. Intellia Therapeutics (NASDAQ:NTLA) is up 150%. Folks, the Genomic Revolution is here. And while everyone can see those big
0 Comments
A leader in the online sports gambling industry, DraftKings (NASDAQ:DKNG) is expanding its presence across the States and is expected to benefit from the upcoming football season. The company is making well-timed moves to build new offerings and achieve growth. It has successfully partnered with some of the top sports companies to offer a unique experience
0 Comments
Since before Robinhood (NASDAQ:HOOD) stock went public a month ago, the phrase “Robinhood stock” has been part of the vocabulary. Source: dennizn / Shutterstock.com These are stocks beloved of small investors, who often trade on Robinhood’s app and exchange views on Reddit’s r/Wallstreetbets. But after looking at its June quarter earnings report and what has
0 Comments
It’s been a little more than three weeks since Zomedica (NYSEAMERICAN:ZOM) reported its Q2 results. Despite reasonably healthy sales, ZOM stock gained just 14% from Aug. 11 through the end of the month.  Source: Postmodern Studio / Shutterstock.com Another InvestorPlace columnist, Ian Bezek, recently argued that Zomedica needs to raise its revenues considerably before investors
0 Comments
After Digital Turbine (NASDAQ:APPS) posted its fiscal first-quarter results, investors appeared to be disappointed by its earnings. APPS stock fell after the earnings report, despite providing good fiscal Q2 guidance. Indeed, the mobile advertising platform firm has multiple catalysts ahead that will sustain the company’s growth. Source: Apple.com The Street is shortsighted as usual and
0 Comments
In this article CHPT CHWY SIG HRC LE HRL Check out the companies making headlines before the bell: Hormel (HRL) – The food producer reported adjusted quarterly earnings of 39 cents per share, matching forecasts, with revenue coming in above estimates. However, Hormel gave a weaker-than-expected full-year outlook, noting the impact of higher costs, although
0 Comments